15.1 million euros have been awarded to 14 excellent projects under the call JTC 2022 on “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”.
The awarded projects are listed below in alphabetical order according to their acronym.
|ANGELA||Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning|
|BileCanMet||Precision medicine in cholangiocarcinoma: accurate tools for early detection and identification of PRMT5 as a novel pharmacological target|
|CAR4PDAC||Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC|
|iCC-Strat||Risk stratification and subtyping of intrahepatic cholangiocarcinoma for early detection of recurrence and response to immuno-therapy|
|IdeaTMEHCC||Identification of therapeutic targets using HCC DErived organoid Augmented with TME components.|
|MATTO-GBM||Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma|
|NK-4-GBM||Metabolically optimised NK cell therapies for Glioblastoma|
|PaCaNano||Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure|
|PANC-P53||Innovative peptide- and RNA-based strategies to modulate p53 for pancreatic cancer therapy|
|PLASTIG||Tackling tumor heterogeneity and PLASTIcity as resistance mechanisms in Glioblastoma|
|PRECEDENCE||Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance.|
|ReachGLIO||Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.|
|SIMMBAP||Systemic immunological determinants of tumor evolution and therapy response in BRCA-mutated pancreatic cancer|
|T-Plex EAC||T-Plex-Capture: Isolation of neoantigen-specific CD8+ T cell receptors for patient-specific immunotherapy in esophageal adenocarcinoma (EAC)|